The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastoma.
Schneider M, Potthoff AL, Ahmadipour Y, Borger V, Clusmann H, Combs SE, Czabanka M, Dührsen L, Etminan N, Freiman TM, Gerlach R, Gessler F, Giordano FA, Gkika E, Goldbrunner R, Güresir E, Hamou H, Hau P, Ille S, Jägersberg M, Keric N, Khaleghi-Ghadiri M, König R, Konczalla J, Krenzlin H, Krieg S, McLean AL, Layer JP, Lehmberg J, Malinova V, Meyer B, Meyer HS, Miller D, Müller O, Musahl C, Pregler BEF, Rashidi A, Ringel F, Roder C, Rössler K, Rohde V, Sandalcioglu IE, Schäfer N, Schaub C, Schmidt NO, Schubert GA, Seidel C, Seliger C, Senft C, Shawarba J, Steinbach J, Stöcklein V, Stummer W, Sure U, Tabatabai G, Tatagiba M, Thon N, Timmer M, Wach J, Wagner A, Wirtz CR, Zeiler K, Zeyen T, Schuss P, Surges R, Fuhrmann C, Paech D, Schmid M, Borck Y, Pietsch T, Struck R, Radbruch A, Helmstaedter C, Németh R, Herrlinger U, Vatter H.
Schneider M, et al. Among authors: roder c.
BMC Cancer. 2025 Feb 20;25(1):306. doi: 10.1186/s12885-025-13682-3.
BMC Cancer. 2025.
PMID: 39979825
Free PMC article.
Clinical Trial.
